Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?

Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cioffi, Michele, Heeschen, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382890/
https://www.ncbi.nlm.nih.gov/pubmed/22754787
_version_ 1782236568468062208
author Cioffi, Michele
Heeschen, Christopher
author_facet Cioffi, Michele
Heeschen, Christopher
author_sort Cioffi, Michele
collection PubMed
description Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells, which resulted in long-term survival of preclinical xenografts models.
format Online
Article
Text
id pubmed-3382890
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33828902012-07-01 Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease? Cioffi, Michele Heeschen, Christopher Oncoimmunology Author's View Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic approach using the EpCAM/CD3-bispecific antibody MT110 is capable of activating and redirecting cytotoxic T cells to eliminate primary human pancreatic cancer stem cells, which resulted in long-term survival of preclinical xenografts models. Landes Bioscience 2012-07-01 /pmc/articles/PMC3382890/ /pubmed/22754787 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Cioffi, Michele
Heeschen, Christopher
Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title_full Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title_fullStr Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title_full_unstemmed Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title_short Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?
title_sort immuno-targeting of pancreatic cancer stem cells: a new therapeutic strategy against a devastating disease?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382890/
https://www.ncbi.nlm.nih.gov/pubmed/22754787
work_keys_str_mv AT cioffimichele immunotargetingofpancreaticcancerstemcellsanewtherapeuticstrategyagainstadevastatingdisease
AT heeschenchristopher immunotargetingofpancreaticcancerstemcellsanewtherapeuticstrategyagainstadevastatingdisease

Ejemplares similares